Study Details

Back to Search Results

A study into pain relief given by ASP8477 for peripheral neuropathic pain (either post-herpetic neuralgia or painful diabetic peripheral neuropathy) and its safety

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT02065349

Astellas Study ID

The unique identification code given by the study sponsor.

8477-CL-0020

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

2013-002521-27

Follow Trial

Condition

Shingles, Neuropathic Pain

Phase

These clinical trials are done to learn if an experimental treatment helps participants who have a specific condition or disease. Phase 2 trials usually include a larger group of participants than Phase 1 trials.

Phase 2

Age

18 years - N/A

Sex

Female & Male

Product

N/A

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Feb 2014 - Feb 2015

Masking

Double (Participant, Investigator)

Enrollment number

132

A Phase 2a Enriched Enrollment Randomized Withdrawal Study to Assess Analgesic Efficacy and Safety of ASP8477 in Subjects with Peripheral Neuropathic Pain

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A study into pain relief given by ASP8477 for peripheral neuropathic pain (either post-herpetic neuralgia or painful diabetic peripheral neuropathy) and its safety? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Site: PL48003

Bialystok, Poland, 15-950

Site: GB44001

Glasgow, United Kingdom, G12OYN

Site: GB44006

London, United Kingdom, SE17EH

Site: CZ42002

Slezska Ostrava, Czech Republic, 710 00

Site: DE49005

Neuss, Germany, 41460

Site: CZ42011

Olomouc, Czech Republic, 77900

Site: CZ42003

Chocen, Czech Republic, 561 01

Site: DE49003

Koeln, Germany, 50937

Site: PL48001

Poznan, Poland, 61-655

Site: GB44003

Ipswich, United Kingdom, IP45PD

Site: CZ42001

Rychnov nad Kneznou, Czech Republic, 516 01

Site: CZ42014

Praha 2, Czech Republic, 12000

Site: PL48005

Warszawa, Poland, 00-465

Site: PL48004

Poznan, Poland, 60-773

Site: CZ42004

litomysl, Czech Republic, 517 14

Site: PL48002

Torun, Poland, 87-100

Site: GB44002

Manchester, United Kingdom, M320UT

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo